Publication:
The predictors of remission in major depressive disorder

dc.contributor.buuauthorAkkaya, Cengiz
dc.contributor.buuauthorEker, Salih Saygın
dc.contributor.buuauthorSarandöl, Aslı
dc.contributor.buuauthorCangür, Şengül
dc.contributor.buuauthorKirli, Selçuk
dc.contributor.departmentTıp Fakültesi
dc.contributor.departmentPsikiyatri Ana Bilim Dalı
dc.contributor.researcheridEKJ-8427-2022
dc.contributor.researcheridQ-9477-2019
dc.contributor.researcheridFVU-6404-2022
dc.contributor.researcheridJHH-9596-2023
dc.contributor.researcheridCZU-1387-2022
dc.contributor.scopusid14061855100tr_TR
dc.contributor.scopusid36341064200tr_TR
dc.contributor.scopusid14020405100tr_TR
dc.contributor.scopusid8604063700tr_TR
dc.contributor.scopusid14019745700tr_TR
dc.date.accessioned2024-04-02T05:25:34Z
dc.date.available2024-04-02T05:25:34Z
dc.date.issued2013
dc.description.abstractBackground: We aimed to determine the predictors of remission in major depressive disorder (MDD) with antidepressant treatment (AT). Methods: The subjects were recruited from the databases of the previous four studies. 178 patients were separated in to two groups at the final visit regarding remission. The patients were analyzed in terms of sociodemographic and clinical features regardless of their AT. Results: The difference in sociodemographic and clinical features was insignificant between the groups. Remitted patients had lower scores on the Hamilton Depression Rating Scale (HDRS), Montgomery-Asberg Depression Scale, Hamilton Anxiety Rating Scale, and the Clinical Global Impression Scale compared to baseline whereas Social Adaptation Self-evaluation Scale (SASS) scores were higher. To evaluate the impact of basal scores of HDRS and SASS on non remission rates, logistic regression analysis was performed. The analysis result was significant (p<0.001). Valid classification rate was 66% for this model. For this model, the scores of HDRS and SASS at visit 1 are significant risk factors for non-remission (p<0.001). As the value of HDRS increases, the risk of non-remission increases 1.095 fold (Odds ratio 95%, confidence interval: 1.045-1.147), whereas as the value of SASS decreases the risk of non-remission increases 1, 076 fold (Odds ratio 95%, confidence interval: 1.042-1.114). For each patient non-remission possibility can be predicted by "p(non remission)=1/[(1+exp (-0, 093xV1HDRS+0, 075xV1SASS)]" equivalent via this model. Conclusion: The findings of the present study suggest that severe level of depression, anxiety and social maladaptation at baseline are more likely to predict remission.en_US
dc.identifier.citationZengin, S. (2013). “The predictors of remission in major depressive disorder”. Noropsikiyatri Arsivi, 50(2), 122-129.tr_TR
dc.identifier.doihttps://doi.org/10.4274/npa.y6279
dc.identifier.endpage129tr_TR
dc.identifier.issn1300-0667
dc.identifier.issn1309-4866
dc.identifier.issue2tr_TR
dc.identifier.scopus2-s2.0-84878930305tr_TR
dc.identifier.startpage122tr_TR
dc.identifier.urihttps://hdl.handle.net/11452/40896
dc.identifier.volume50tr_TR
dc.identifier.wos000320972700005
dc.indexed.scopusScopusen_US
dc.indexed.trdizinTRDizintr_TR
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.relation.journalTürk Nöropsikiyatri Derneğitr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNeurosciences & neurologyen_US
dc.subjectMajor depressive disorderen_US
dc.subjectRemissionen_US
dc.subjectAntidepressanten_US
dc.subjectPost-hoc analysisen_US
dc.subjectClinical predictorsen_US
dc.subjectTreatment responseen_US
dc.subjectFamily-historyen_US
dc.subjectRating-scaleen_US
dc.subjectDouble-blinden_US
dc.subjectEfficacyen_US
dc.subjectSertralineen_US
dc.subjectTolerabilityen_US
dc.subject.emtreeAntidepressant agenten_US
dc.subject.emtreeAnxietyen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeClinical featureen_US
dc.subject.emtreeClinical Global Impression scaleen_US
dc.subject.emtreeConsultationen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeDemographyen_US
dc.subject.emtreeDisease severityen_US
dc.subject.emtreeHamilton Anxiety Scaleen_US
dc.subject.emtreeHamilton scaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMajor depressionen_US
dc.subject.emtreeMaladjustmenten_US
dc.subject.emtreeMontgomery Asberg Depression Rating Scaleen_US
dc.subject.emtreePredictionen_US
dc.subject.emtreePsychological rating scaleen_US
dc.subject.emtreeRemissionen_US
dc.subject.emtreeRisk factoren_US
dc.subject.emtreeSocial Adaptation Self evaluation Scaleen_US
dc.subject.emtreeSocial statusen_US
dc.subject.scopusMorpholines; Reboxetine; Amino Alcoholsen_US
dc.subject.wosClinical neurologyen_US
dc.titleThe predictors of remission in major depressive disorderen_US
dc.title.alternativeMajör depresif bozuklukta düzelmenin öngörücüleritr_TR
dc.typeArticleen_US
dspace.entity.typePublication
local.contributor.departmentTıp Fakültesi/Psikiyatri Ana Bilim Dalıtr_TR
local.contributor.departmentTıp Fakültesi/Biyoistatistik Ana Bilim Dalıtr_TR

Files

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: